Avizakimab, formerly known as BOS161721, represents a novel therapeutic approach to treating immune-mediated disorders. This biological agent selectively targets IL18, a key cytokine implicated in the https://estellechkk468513.blognody.com/50381392/avizakimab-a-thorough-exploration-into-bos161721-s-capability